Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC1 cell therapy for post-traumatic syringomyelia
2015-002383-16Phase 2Completed
- Sponsor
- Fundación de Investigación Biomédica Hospital Puerta de Hierro
- Start
- Oct 2015
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow stromal cells in Post-traumatic syringomyelia (PTS) and spinal cord injury (SCI), sponsored by Fundación de Investigación Biomédica Hospital Puerta de Hierro. Primary endpoint: Neurological and functional scale changes. Started Oct 2015; status: completed.
02
Drugs
autologous bone marrow stromal cells
03
Conditions
Post-traumatic syringomyelia (PTS)spinal cord injury (SCI)
Beyond the preview
Go deeper on 2015-002383-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002383-16.